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Abstract
Background & Aim: Radiofrequency ablation (RFA) is an effective treatment for single
hepatocellular carcinoma (HCC) 3cm. Disease recurrence is common, and in some patients will
occur outside transplant criteria. We aimed to assess the incidence and risk factors for recurrence
beyond Milan criteria (MC) in potentially transplantable patients treated with RFA as first-line
therapy.
Methods: We performed a retrospective cohort study of potentially transplantable patients with
new diagnoses of unifocal HCC 3cm that underwent RFA as first-line therapy between 2000-
2015. We defined potentially transplantable patients as those aged <70 years without any
comorbidities that would preclude transplant surgery. Incidence of recurrence beyond MC was
compared across two groups according to HCC diameter at the time of ablation: (HCC 2cm vs.
HCC>2cm). Competing risks Cox regression was used to identify predictors of recurrence
beyond MC.
Results: We included 301 patients (167 134 HCC>2cm). Recurrence beyond MC
respectively (p=0.01). The 1-, 3- and 5-years actuarial survival after RFA was 98.2%, 86.2% and
(p=0.01).
Tumor size >2cm [HR 1.94 (95%CI 1.25-3.02)] and alpha fetoprotein levels at the time of
ablation [100-1000ng/mL: HR 2.05 (95%CI 1.10-3.83)] were found to be predictors of post-RFA
recurrence outside MC.
Conclusion: RFA for single HCC 3cm provides excellent short- to medium-term survival.
However, we identified patients at higher risk of recurrence beyond MC. For these patients, liver
transplantation should be considered right after the first HCC recurrence after RFA.
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Lay Summary
Radiofrequency ablation (RFA) and liver transplantation are treatment options for early-stages of
hepatocellular carcinoma (HCC). After RFA some patients will experience recurrence or
metastatic spread of the initial tumor, or may develop new tumors within the liver. Despite close
follow-up, these recurrences can in some cases progress rapidly and exceed transplant criteria,
thereby preventing the patient from receiving a transplant and losing the potential for cure. In
this study, we investigated the incidence and risk factors for recurrence beyond transplant criteria
in patients treated with RFA that could have otherwise received a transplant. Among 301
patients, recurrence beyond transplant criteria occurred in 28%, despite undergoing close
radiological follow-up. We identified that patients with HCC >2cm and higher serum alpha
fetoprotein are at greater risk of recurrence beyond the transplant criteria. These data suggest that
liver transplantation should be considered right after the first HCC recurrence for these patients.
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Highlights
Most transplantable RFA
will eventually develop recurrent HCC distant to the ablation site.
Many transplantable patients treated with HCC will recur beyond the Milan criteria
despite close post-RFA surveillance, losing the opportunity for cure.
Transplantable patients with tumors >2cm and higher serum alpha fetoprotein have
higher risk of recurrence beyond Milan criteria.
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Introduction
The optimal approach for transplantable patients with early unifocal HCC is unclear.
Small HCC (BCLC-0 or A) can be treated with ablation, liver resection, or liver transplantation
(LT) as first-line therapies.1 Although the results of LT are excellent, most jurisdictions currently
only assign MELD exception points to patients with larger HCC based on the belief that if
resection or RFA do not work, transplantation can be undertaken as a second curative
procedure.2
Radiofrequency ablation (RFA) of early HCC provides a 90% complete response3 and a
5-year survival rate of 66-86% even in candidates unfit for resection.4,5 Outcomes following
RFA are similar to surgical resection, especially for lesions smaller than 3 cm.6 HCC recurrence
after ablation of small HCC occurs in up to 60-80% of patients by 5-years, mainly due to de
novo tumors.7,8 Unfortunately, there is little data on how often these recurrences exceed the
criteria for a potentially curative liver transplant.9 The present study was therefore undertaken to
assess the incidence and risk factors for HCC recurrence outside of the Milan criteria (MC) after
locoregional therapies in patients with unifocal HCC less than or equal to 3cm who were treated
with RFA and had no contraindications for LT at the time of ablation. Our primary aim was to
identify the characteristics of patients for whom transplantation might be the best first-line
treatment.
Methods
Study Design and Population
This is a retrospective cohort study from a large academic institution, the University
Health Network (UHN) in Toronto, Canada. We assessed all -years old) with new
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diagnoses of solitary HCC up to 3cm who underwent RFA between February 1st, 2000 and
March 31st, 2015. All patients included in this study were reviewed by the UHN HCC
Multidisciplinary Board and were determined to be most appropriate for RFA as first-line
treatment. In our institution, all treatment decisions are individualized after a combined
consideration of tumor size, location, liver function, patient comorbidities, and functional status.
Patients with profound liver dysfunction (MELD >15) are typically referred for transplant
consideration as definitive therapy. In patients with well compensated liver function, either RFA
or surgery are offered as first line treatment. For lesions <2.0cm, RFA is offered as first line
therapy. For lesions between 2.0 and 2.5 cm, surgical resection or RFA are offered depending on
tumor location and patient characteristics. Patients with solitary tumor between 2.5 and 3 cm are
offered resection. Those that are not suitable for resection are evaluated on a case-by-case basis
for either RFA or transplantation. The choice between ablation or LT is made based on tumor
location and severity of underlying liver disease by consensus at the UHN HCC
Multidisciplinary Board. Portal hypertension was diagnosed in most cases with indirect measures
(platelet count <100.000 and or elevated bilirubin and/or elevated bilirubin and/or presence of
varices and/or splenomegaly). In cases where it was unclear, direct measurement was performed
with a hepatic venous pressure gradient, where significant portal hypertension was defined as a
gradient 10 mmHg. Supplementary Figure 1 shows the algorithm for the solitary HCC 3cm
at our institution.
The study population was composed of those patients that fulfilled all of the following
inclusion criteria: 1) new diagnosis of HCC based on imaging criteria consistent with
international guidelines10 or by histological assessment of a radiologically indeterminate tumor;
2) single HCC up to 3cm in maximum diameter; 3) not a resection candidate 4) the patient
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underwent RFA as first-line therapy for their HCC; 5) patients had achieved tumoral complete
response after a single ablation procedure; 6) the patient was otherwise a transplantable
candidate at the time of ablation. Transplantability was defined as any patient younger than 70
years old, with no medical comorbidities that would preclude transplantation. Complete response
was defined with the mRECIST criteria.11 Patients who did not achieve complete tumoral
response after the first RFA, who did not qualify as transplantable, or underwent any other HCC
treatment before the first HCC recurrence were excluded. Patients who did not have complete
response after the first ablation were excluded to homogenize the cohort, as we were most
interested in the natural history of post-ablation disease recurrence, rather than incompletely
ablated tumors. RFA was considered a bridging treatment if
the patient was already listed for LT (due to decompensated cirrhosis) and thereafter developed
HCC while listed; or if the indication for transplant was decompensated cirrhosis in association
with HCC, and the patient was therefore listed for LT prior to any HCC recurrence. Patients that
received RFA as a bridge to transplant were excluded from this analysis. Patients were divided in
two groups according to the HCC size at the time of ablation 2cm and HCC >2cm. This
study was approved by the UHN Research Ethics Board (CAPCR ID 16-5285). This study
complies with the ethical guidelines of the 1975 Declaration of Helsinki and no organs from
prisoners were used in this research. This study complies with the STROBE Statement for
observational studies.12
Ablation Techniques
Patients were considered eligible for RFA under the following conditions: single HCC
under 3cm, acceptable liver function (Child-Pugh A or B), no encephalopathy (unless previous
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mild encephalopathy and currently well controlled medically), and tumors were amenable to an
image guided procedure [ultrasound (US), computed tomography (CT) or combined US and CT].
Patients with well controlled ascites were considered eligible if all other conditions were met.
RFA was performed as an outpatient procedure. All procedures were performed by the same
team of interventional radiologists. All procedures were performed percutaneously using local
anesthesia and moderate sedation. HCCs were treated with LeVeen electrodes (Boston
Scientific, Natick, MA) or Cool-tip electrodes (Medtronic, Minneapolis, MN), according to
protocols. The intraprocedural monitoring was made with
ultrasound for those lesions visible sonographically to ensure the hyperechoic ablation zone
produced encompasses with adequate tumoral margins. For lesions that were sonographically
occult, CT was applied to adequate needle positioning prior to ablation and post-ablation to
ensure ablation zone was appropriate location and size to encompass lesion. Following RFA
treatment, patients underwent serum alpha-fetoprotein (AFP) measurements and contrast
enhanced CT or magnetic resonance (MR) imaging at one-month after the primary procedure
and, thereafter at 3 monthly intervals for two years, before reverting to 6-month ultrasound if no
recurrent disease was identified. Chest CT was performed every 6 months for the first two years
after ablation.
Patterns of Recurrence after RFA
The primary outcome was HCC recurrence beyond MC. This was assessed as a time-to-
event variable. All patients underwent surveillance after ablation as previously described. HCC
recurrence following RFA was defined by a new lesion on imaging, either radiologically
compatible with HCC or confirmed by histology. Recurrence was classified as local intrahepatic
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(when the enhancing tumor reappeared at the previous ablation zone), distant intrahepatic (a new
intrahepatic HCC at a separate location to the ablation zone) or extrahepatic (HCC outside the
liver). Patients with more than one type of recurrence were classified according to the size of the
greater intrahepatic tumor or as extrahepatic recurrence if an extrahepatic HCC were present.
Recurrence beyond MC was defined as recurrence with tumor size greater than 5cm for a single
tumor, greater than 3cm for up to 3 tumors, more than 3 tumor deposits, macrovascular invasion,
or extrahepatic disease. Patients were classified as within or beyond MC at the time of first
recurrence (i.e. at the first-time patient had recurrent HCC diagnosed after ablation). Patients
who were deemed within MC at the time of first recurrence could have undergone further
ablation and recurrence beyond MC could be diagnosed at any time during the follow-up.
Treatments of recurrence after ablation
At the time of HCC recurrence all patients were re-presented at HCC multidisciplinary
rounds. Our general policy has been to re-ablate the intrahepatic HCC recurrence applying the
same criteria we use for the primary treatment. Otherwise, if unsuitable for repeat RFA, patients
salvage LT based on a combined assessment of tumor
stage, liver function, and comorbidities. Other locoregional therapies such as transarterial
chemoembolization would be considered if patients were not candidates for either ablation,
surgery or transplantation, or used as bridging therapy to transplantation. We recorded the first
treatment that was provided after recurrence. For those listed for transplantation at the time of
recurrence, we recorded their outcome in the waiting list (i.e. whether they dropped out or were
actually transplanted). Causes of death were also recorded and classified as related to HCC
progression or not.
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Statistical Methods
Statistical methods included a descriptive assessment of our cohort using mean/standard
deviation for normally distributed continuous variables, median/interquartile range (IQR) for
non-normally distributed continuous variables, and counts/percentages for categorical variables.
Differences between groups in terms of baseline variables and outcomes post RFA were
determined using Chi-squared test for categorical variables, student T-test for normally
distributed continuous variables, and Mann Whitney U test for non-normally distributed
continuous variables. primary outcome was time to recurrence beyond MC. Other
outcomes of interest were overall recurrence beyond MC, overall HCC recurrence, recurrence-
free survival and overall survival. Time to recurrence beyond MC was defined between the date
of RFA and the date diagnosis of recurrence beyond MC. We took into account the competing
risks between death not related to HCC and recurrence beyond MC. Recurrence-free survival
was defined between the date of ablation and the date of diagnosis of HCC recurrence or death.
To avoid cofounding disease-recurrence outcomes, patients who underwent LT as treatment for
recurrent disease were censored at the date of transplant. The recurrence beyond MC
probabilities and survival probabilities were estimated by the Kaplan-Meier method and
compared between groups using the logrank test. Univariate and multivariate Cox regression
were performed to assess predictors for post-ablation recurrence beyond MC. All variables at
baseline were included in the model and the final model was selected by stepwise backward
approach. AFP levels were categorized as previously validated by Duvoux et al.13 Patients were
divided in 3 categories according to their serum AFP: <100 ng/mL, 100-1000 ng/mL and >1000
ng/mL. Proportional-hazard assumptions were evaluated using Schoenfeld residuals when
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applicable. To assess the potential impact of tumoral differentiation in the outcome, we repeated
the analysis for the subgroup of patients who had tumoral differentiation information available.
Results of these analyses are presented with hazard ratios (HR) with a 95% confidence interval
(95% CI). All statistical testing was performed in Stata 15.0 (Stata Corp., College Station, TX).
The median follow-up was 3.6 (IQR 2.1-5.5) years and 23 (7.6%) patients had less than 2-years
of follow-up.
Results
Study Population
Between February 2000 and March 2015, a total of 635 patients with unifocal HCC
smaller than 3cm underwent RFA. Of those, 195 patients were older than 70-years or had
medical contraindications for LT at the time of ablation, 35 patients did not achieve complete
response with the first RFA and 104 underwent ablation as a bridge to LT and were excluded
from the study. Of these 104 bridged patients, 93 had already been listed for LT for
decompensated cirrhosis and developed an HCC while listed, and 11 patients were listed for LT
for decompensated cirrhosis prior to any HCC recurrence. The study group was therefore
composed of 301 patients (Figure 1). The median age was 59-years old (IQR 53 64) and 221
(73.4%) patients were male. Regarding the etiology of liver disease, 135/301 (44.9%) patients
had chronic hepatitis C (HCV) and 106/301 (35.2%) had chronic hepatitis B (HBV). The median
MELD score at the time of RFA was 9 (IQR 7 11) and 261/301 (86.7%) patients were Child-
Pugh class A. No patients were Child-Pugh class C. The median tumor size at the time of RFA
was 2cm (IQR 1.6-2.5). HCC histology at the time of RFA was available in 180/301 (59.8%)
patients; 38/180 (21.1%), 134/180 (74.4%), and 8/180 (4.5%) of those patients had well,
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8
moderate, and poorly differentiated HCC respectively. Prior to ablation, serum AFP was
available in 276/301 (91.7%) patients and the median serum AFP was 9 ng/mL (IQR 5-46).
Characteristics of the study cohort are summarized in Table 1.
2 and >2cm
According to the tumor size at the time of the first ablation, 167/301 (55.5%) patients had
an 134/301 (44.5%) patients had an
were slightly younger (57.6 vs. 60.1, p=0.01) and less likely to have had a biopsy of the tumor
(50.9% vs. 70.9%, p=0.001). There were no statistically significant differences between patients
in terms of sex, MELD, Child-Pugh score and serum AFP. Among patients with an available
biopsy, patients with HCC >2cm had greater proportion of moderately differentiated HCC [HCC
55 (64.7%) patients vs. HCC >2cm 79 (83.2%) patients, p=0.012]. The baseline
characteristics of the two groups are summarized in Table 1.
Tumor Recurrence
HCC recurrence was diagnosed in 199/301 (66.4%) patients. According to initial HCC
diameter at the time of ablation, 105 (62.9%) patients in the HCC 2cm and 94 (70.1%) patients
in the in the HCC >2cm group experienced eventual recurrence (p=0.18). The median
recurrence-free survival was 1.98 (95% CI 1.57-2.40) years for the whole cohort. The median
recurrence-free survival was 2.5 (95% CI 1.85-3.15) years for those with HCC 2cm and 1.52
(95% CI 1.24-1.81) years for those with HCC >2cm (p=0.01) (Figure 2-A). The 1-, 3-, and 5-
year cumulative recurrence rate was 26.9%, 53.9% and 62.9 group vs.
34.3%, 67.9% and 70.9% in the HCC >2cm group (p<0.001).
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Patterns of HCC Recurrence After Ablation
The first episode of recurrence after ablation occurred as distant intrahepatic recurrence
in 139 (46.2%) patients, whereas 50 (16.6%) patients had local recurrence and 10 (3.3%) patients
had extrahepatic recurrence. The time to recurrence was 1.1 years (IQR 0.6-2.4) in those with
distant intrahepatic vs. 0.9 year (IQR 0.5-1.8) in those with local recurrence, and 1.5 years (IQR
0.4-2.9) in those with extrahepatic disease (p=0.42). Table 2 shows the patterns of recurrence
among the study groups.
Among patients with chronic hepatitis C, 12 (8.9%) patients had achieved sustained
virologic response at the time of ablation. The rate of recurrence was 8.9% for patients with
HCV and SVR and 8.8% for patients with HCV without SVR (p=0.99). Among the 106 patients
with chronic hepatitis B, 91 (85.8%) were suppressed at the time of ablation. The rate of
recurrence among patients with HBV and virologic suppression was 59.3% and among patients
with HBV without virologic suppression was 66.7% (p=0.59).
Tumor Recurrence Beyond Milan criteria
During follow-up, 83 (27.6%) patients had eventual recurrence beyond MC within a
median time of 0.9 (IQR 0.5-1.8) years. According to initial tumor size, 36 (21.6%) patients in
the HCC 2cm group and 47 (35.1%) patients in the HCC >2cm group had recurrence beyond
MC (p=0.01). Between the two initial HCC diameter groups, there were no differences regarding
the specific reason for exceeding MC (number of lesions, size of lesions, vascular invasion,
extrahepatic disease). Notably, the first recurrence after ablation was already beyond MC in 38
(12.6%) patients: 15/167 (9.0%) in the 2cm group and 23/134 (17.2%) in the HCC >2cm
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group (p=0.03) (Figure 2-B) this was despite post ablation radiological surveillance. The
median time to recurrence amongst patients with first recurrence beyond MC was 1.4 (IQR 0.7-
2.8) years. These patients had regular radiological assessment that showed no recurrence until
the first evidence of tumor recurrence was already beyond Milan criteria. Table 2 summarizes
patterns of recurrence after ablation. Amongst patients who were diagnosed with recurrence
beyond MC at their first recurrence, 13/38 (34.2%) patients had a size or number of tumors that
exceeded criteria, 14/38 (36.8%) had macrovascular invasion and 11/38 (28.9%) had metastatic
disease. Figure 3 provides two cases were recurrence occurred beyond MC.
Treatment after recurrence
and 60/94 (63.8%) patients with initial HCC >2cm underwent repeat RFA, whereas LT was the
13/94
(13.8%) patients in the HCC >2cm group (p=0.28). During the entire duration of follow-up,
group were listed for LT (p=0.76), of whom 30/39 (76.9%) patients with
(54.5%) patients with HCC >2cm were eventually transplanted (p=0.04). The proportion of
patients that dropped-out due to tumor progression was significantly lower in the HCC 2cm
group than the HCC >2cm group [9/39 (23.1%) vs. 15/33 (45.5%)] (p=0.04). Table 3
summarizes treatments after recurrence.
Predictors of Recurrence Beyond Milan Criteria after Ablation
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Table 4 shows the results of univariate and multivariate analyses. Predictors of recurrence
beyond MC were tumor size >2cm [HR 1.94 (95% CI 1.25-3.02)] and AFP at the time of
ablation [HR 2.05 (95% CI 1.10-3.83) for AFP 100-1000 ng/mL]. In a sensitivity analysis of
patients who had tumor biopsies, we identified that poorly differentiated HCC was associated
with increased risk of recurrence beyond MC [HR 4.45 (95% CI 1.20-16.61)] (Supplementary
Table 1).
Overall Survival
Median survival after ablation for the entire cohort was 7.8-years. Figure 4 shows
survival probabilities according to tumor size. The 1-, 3- and 5-years actuarial survival after
ablation was 98.2%, 86.2% and 79.0 cm group vs. 93.3%, 77.6% and 70.9% in
the HCC >2cm group (p=0.01). HCC progression was the cause of death in 75/301 patients
(24.9%) [35/167 (21.0%) patients 2cm group and 40/134 (29.9%) in the HCC >2cm
group (p=0.08)].
Discussion
There are conflicting data on the best management for patients with early stage HCC who
are otherwise candidates for transplant. In this study, small HCC treated with RFA in patients
who would have also been transplant candidates had a 66% recurrence rate. 42% of these
recurrences exceeded the MC disqualifying them from a curative treatment option in
jurisdictions that limit transplantation to the MC. In contrast, if the early stage HCC patients in
this study had been treated with LT instead of RFA we would have expected a 5-year survival
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rate of ~75-80% and a 5-year recurrence rate of <15%.14 Risk factors for recurrences beyond the
MC after RFA included tumors >2cm, and a serum AFP >100ng/mL.
The association between higher recurrence rates after RFA and larger tumor size and
higher AFP levels has been previously documented. Tsuchiya et al. performed a retrospective
study of 323 patients with HCC within MC (including patients with multifocal and larger
tumors) that received first-line RFA9 and identified an AFP level >100ng/mL and tumor size
>2cm as risk factors for recurrence outside MC. Cho et al. included 438 patients with unifocal
HCC <3cm who received first-line RFA.15 Variables associated with initial recurrence beyond
MC included tumor size >2cm and tumor location adjacent to the colon, presumably due to
technical limitations of RFA. None of these studies specifically examined these risk factors in
the select population of potentially transplantable patients who were the subjects of the present
study. We identified a local recurrence rate
with other retrospective studies16,17, but slightly higher than reported in clinical trials18,19. The
probable explanation for this higher incidence when compared to clinical trials is the real-world
nature of our data.
Survival differences after RFA related to initial HCC size have also been previously
reported. Kutlu et al. demonstrated that patients with tumors greater than 3 cm have impaired
survival after RFA when compared to surgery and transplantation.20 However, in contrast with
the present study, survival differences between patients with HCC diameter
were not significant. However, the Kutlu et al. study did not perform an intention-to-treat
comparison, made no distinction about transplant candidacy of included patients at baseline, and
had limited data regarding severity of liver disease, or of recurrence outcomes. In our study, the
5-year overall survival of patients with tumors >2cm was 71%. However, recurrence was almost
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universal. Patients with tumors >2cm had a higher recurrence rate beyond Milan when compared
to those with tumors <2 cm.
This study shows that u treated with
ablation as first line therapy, will recur. The most common location of recurrence was
intrahepatic and distant to the initial ablation site; this is not surprising, given that a past history
of HCC is a well-known risk factor for new lesions.21 New ablation techniques continue to be
developed and utilized, including multi-bipolar22 and microwave ablation23. Since the majority of
our recurrences beyond MC were not local, we speculate that these newer techniques may not
reduce recurrence rates although this question certainly merits further study.
It has been speculated that new direct acting antivirals against HCV may affect HCC
recurrence rate after RFA for HCCs.24 In the present study, we did not find an impact of SVR on
the recurrence rate among patients with HCC treated with RFA but these agents only became
available in Ontario in 2014, towards the end of the interval reviewed in this study. The impact
of SVR on HCC recurrence after RFA remains unresolved and requires further study.
The treatment of recurrent HCC after first-line therapy with ablation is also not
standardized. Re-ablation, liver resection and LT are valid options.25 Because of the organ
supply, many centers utilize further locoregional therapies for recurrence, with salvage transplant
considered on a case-by-case basis.26 However, there is data suggesting that higher survival rates
can be achieved with salvage transplantation as compared with resection or re-ablation for HCC
recurrence.27,28 Most of these studies do not take into account the LT waiting list dropout rate
which was 33% in our series, higher than previous reports.29-31 Drop-out rates are likely higher at
our center because of our practice to list patients for LT with tumors beyond the MC, a group
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with a higher risk of dropout.32 Importantly, the dropout rate was higher for those patients with
initial tumors >2cm when compared to smaller tumors.
A limitation of this study is the retrospective, observational study design. However, in the
current era it would be very challenging to undertake a prospective, randomized trial of different
management strategies for very early/early stage HCC. We did not assess the impact of multi-
bipolar ablation, combined therapies for HCC recurrence (e.g. RFA and TACE) or emerging
therapies such as radioembolization. We do not believe this to be a significant limitation since
RFA remains the most commonly used treatment for early HCC in unresectable patients.5,33
Strengths of this study include the intention-to-treat and competing risks analysis (thereby more
accurately reflecting real-world outcomes) and an outcome measure (recurrence within MC) that
is relevant to most LT centers worldwide.
In summary, our study suggests that transplantation rather than ablation may offer
patients with >2cm tumors or serum AFP >100ng/mL the best chance of cure. In regions where
it is impossible to offer LT as the initial treatment to patients with these risk factors, they should
be considered for enhanced post-treatment surveillance after RFA with prompt referral for LT
whenever there are worrisome findings. The ideal surveillance protocol for patients with high-
risk of post ablation recurrence is still unknown and should be the aim of future investigation.
Conclusion
RFA as first-line therapy for HCC 3cm provides excellent short- to medium-term
survival rates. However, recurrent or new tumors develop in more than 2/3 of these patients. We
identified risks factors for developing recurrence beyond MC including AFP level and tumor size
greater than 2cm. This analysis suggests that patients at higher risk of recurrence beyond MC
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should be considered for LT earlier in their treatment pathway, ideally after their first HCC
recurrence.
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Figures legends:
Fig. 1. Study flowchart.
Fig. 2. A Recurrence-free survival probabilities among patients with HCC >2cm and
first-line ablation. B Cumulative hazards of recurrence beyond Milan
first-line ablation.
Fig. 3. Computed tomography scans showing the control image at 3-months after ablation
(left) and at the time of first recurrence (right). Patient A with multifocal HCC recurrence
12 months after ablation. Patient B with local recurrence and tumoral portal vein
thrombus 18 months after ablation.
Fig. 4. Survival probabilities between transplantable patients with HCC >2cm a
after first-line ablation.
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Table 1: Baseline patient characteristics
Variable Overall
n = 301
Tumor Size
n = 167
HCC >2cm
n = 134
p*
Male (%) 221 (73.4) 128 (77.2) 92 (68.7) 0.11
Age, median (IQR) 58.8 (53.3-64.1) 57.6 (51.5-63.5) 60.1 (55.5-64.6) 0.01
Etiology (%) 0.8
HCV 135 (44.9) 71 (42.5) 64 (47.8)
HBV 106 (35.2) 61 (36.5) 45 (33.6)
ETOH 24 (8) 15 (9) 9 (6.7)
NASH 28 (6) 11 (6.6) 7 (5.2)
Other 18 (6) 9 (5.4) 9 (6.7)
Biopsy, yes (%) 180 (59.8) 85 (50.9) 95 (70.9) 0.01
Differentiation (%) 0.01
Well 38 (21.1) 26 (30.6) 12 (12.6)
Moderate 134 (74.4) 55 (64.7) 79 (83.2)
Poor 8 (4.5) 4 (4.7) 4 (4.2)
AFP, ng/mL, median (IQR) 9 (5-45.8) 8 (5-28) 12 (5-67) 0.06
AFP categories, ng/mL (%) 0.01
0 100 263 (87.4) 150 (89.8) 113 (84.3)
101 1000 28 (9.3) 16 (9.6) 12 (9.0)
>1000 10 (3.3) 1 (0.6) 9 (6.7)
Child-Pugh Score (%) 0.09
A 261 (86.7) 150 (89.8) 111 (82.8)
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B 40 (13.3) 17 (10.2) 23 (17.2)
C 0 0 0
MELD Score, median (IQR) 9 (7-11) 9 (7-11) 9 (7-11) 0.65
median (IQR)
16 (10-23) 15 (10-23) 16 (9-24) 0.94
INR, median (IQR) 1.1 (1.0-1.2) 1.1 (1.03-1.2) 1.09 (1.0-1.2) 0.80
(IQR)
72 (65-83) 72 (65-83) 72 (64-84) 0.57
Albumin (g/L), median (IQR) 39 (35-42) 39 (36-42) 39 (35-42) 0.36
Platelet count (x109/L), median
(IQR)
101 (75-151) 106 (75-155) 98 (75-150) 0.86
Hepatitis C with SVR, yes (%) 12 (15.8) 6 (15.0) 6 (16.7) 0.85
Hepatitis B with suppression,
yes (%)
91 (85.8) 51 (83.6) 40 (88.9) 0.44
* Chi-squared test for categorical variables and the Mann-Whitney U test for continuous variables.
Among 135 patients with viral hepatitis C. Among 106 patients with hepatitis B
HCC: Hepatocellular carcinoma; HCV: Chronic hepatitis C; HBV: Chronic hepatitis B; ETOH: alcoholic
liver disease; NASH: Nonalcoholic steatohepatitis; AFP: Alpha fetoprotein.
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Table 2: Patterns of recurrence after RFA as first-line therapy for .
Recurrence patterns Overall
n = 301
According to HCC size
n = 167
HCC >2cm
n = 134
p*
Recurrence, yes (%) 199 (66.1) 105 (62.9) 94 (70.1) 0.18
First recurrence type (%)
Local 47 (15.6) 20 (12) 27 (20.1) 0.07
Distant intrahepatic 139 (46.2) 81 (48.5) 58 (43.3) 0.38
Distant extrahepatic 10 (3.3) 2 (1.2) 8 (5.9) 0.02
Beyond Milan criteria (%)
At first recurrence 38 (12.6) 15 (9.0) 23 (17.2) 0.03
At any time during the follow-up 83 (27.6) 36 (21.6) 47 (35.1) 0.01
Reason to being classified as beyond
Milan criteria (%)
Tumor size and/or number 29 (34.9) 11 (30.6) 18 (38.3) 0.78
Macrovascular invasion 30 (36.1) 15 (41.7) 15 (31.9) 0.36
Metastatic disease 24 (28.9) 10 (27.8) 14 (29.8) 0.84
* Chi-squared test for categorical variables and the Mann-Whitney U test for continuous variables.
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Among the 83 patients who had recurrence beyond Milan Criteria. HCC: Hepatocellular carcinoma.
Table 3: Treatment after first recurrence and listing outcomes
Recurrence treatment Overall
n = 199
According to HCC size
n = 105
HCC >2cm
n = 94
p*
First treatment after recurrence (%) 0.45
Repeated ablation 141 (70.9) 81 (77.1) 60 (63.8)
Liver Transplant 20 (10.1) 7 (6.7) 13 (13.8)
TACE 7 (6.4) 3 (2.9) 6 (6.4)
Liver resection 6 (3.0) 3 (2.9) 3 (3.2)
SBRT 11 (5.5) 6 (5.7) 5 (5.3)
Sorafenib 2 (1.0) 0 2 (2.1)
Best supportive care 10 (5.0) 5 (4.8) 5 (5.3)
Listed for liver transplant anytime
during follow-up (%)
72 (36.2) 39 (37.1) 33 (35.1) 0.76
Wait list outcome (%)
Dropout 24 (33.3) 9 (23.1) 15 (45.5) 0.04
Underwent LT 48 (66.7) 30 (76.9) 18 (54.5)
* Chi-squared test for categorical variables and the Mann-Whitney U test for continuous
variables.
HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; SBRT: Stereotactic body
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radiation therapy.
Table 4: Multivariable regression model to predict recurrence beyond Milan criteria in
first-line RFA
Variable Univariable Multivariable
HR (95% CI) p HR (95% CI) p*
Sex [ref.: male] 1.37 (0.80-2.32) 0.25 - -
Age 1.00 (0.97-1.03) 0.84 - -
Etiology of liver disease [ref.: HCV]
HBV 0.75 (0.46-1.23) 0.26 - -
ETOH 0.58 (0.24-1.37) 0.21 - -
NASH 0.16 (0.02-1.21) 0.08 - -
Other 1.04 (0.48-2.25) 0.92 - -
HCC size, cm 1.46 (0.88-2.44) 0.14 - -
HCC size [ref.:
>2cm 1.94 (1.27-2.99) 0.01 1.94 (1.25-3.02) 0.01
AFP, ng/mL 1.00 (0.99-1.01) 0.90
100ng/mL]
101 1000ng/mL 1.98 (1.06-3.70) 0.03 2.05 (1.10-3.83) 0.02
>1000ng/mL 2.64 (1.06-6.55) 0.04 2.06 (0.82-5.17) 0.12
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Child-Pugh score [ref.: A]
B 0.83 (0.40-1.75) 0.63 - -
MELD 1.05 (0.98-1.13) 0.16 - -
Platelets (x109/L) 1.00 (0.99-1.01) 0.21 - -
Hepatitis C with SVR [ref.: no] 0.82 (0.29-2.31) 0.71 - -
Hepatitis B with suppression [ref.:
no]
0.97 (0.38-2.81) 0.96 - -
* Stepwise backwards Cox regression.
HCV: Chronic hepatitis C; HBV: Chronic hepatitis B; ETOH: alcoholic liver disease;
NASH: Nonalcoholic steatohepatitis; HCC: Hepatocellular carcinoma; AFP: Alpha
fetoprotein.
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Highlights
will eventually develop recurrent HCC distant to the ablation site.
Many transplantable patients treated with HCC will recur beyond the Milan criteria
despite close post-RFA surveillance, losing the opportunity for cure.
Transplantable patients with tumors >2cm and higher serum alpha fetoprotein have
higher risk of recurrence beyond Milan criteria.
*Highlights
